Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1890-25-1

Post Buying Request

1890-25-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1890-25-1 Usage

Synthesis Reference(s)

Tetrahedron Letters, 21, p. 4687, 1980 DOI: 10.1016/0040-4039(80)88094-4

Check Digit Verification of cas no

The CAS Registry Mumber 1890-25-1 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,8,9 and 0 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1890-25:
(6*1)+(5*8)+(4*9)+(3*0)+(2*2)+(1*5)=91
91 % 10 = 1
So 1890-25-1 is a valid CAS Registry Number.

1890-25-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name Spiro[5.5]undecan-3-one

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1890-25-1 SDS

1890-25-1Relevant articles and documents

Mn(III)-Based Oxidative Fragmentation-Cyclization Reactions of Unsaturated Cyclobutanols

Snider, Barry B.,Vo, Nha Huu,Foxman, Bruce M.

, p. 7228 - 7237 (1993)

Alylic cyclobutanols 1, 10, 21, 27, 32, 39, 51 and 58 are oxidatively fragmented by Mn(OAc)3*2H2O in EtOH to give tertiary radicals as shown in eq 1.These tertiary radicals undergo both 6-endo-cyclization to the α,β-unsaturated ketone to afford α-keto rad

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

-

, (2021/01/22)

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

Pichia stipitis OYE 2.6 variants with improved catalytic efficiencies from site-saturation mutagenesis libraries

Patterson-Orazem, Athéna,Sullivan, Bradford,Stewart, Jon D.

, p. 5628 - 5632 (2015/01/09)

An earlier directed evolution project using alkene reductase OYE 2.6 from Pichia stipitis yielded 13 active site variants with improved properties toward three homologous Baylis-Hillman adducts. Here, we probed the generality of these improvements by testing the wild-type and all 13 variants against a panel of 16 structurally-diverse electron-deficient alkenes. Several substrates were sterically demanding, and as hoped, creating additional active site volume yielded better conversions for these alkenes. The most impressive improvement was found for 2-butylidenecyclohexanone. The wild-type provided less than 20% conversion after 24 h; a triple mutant afforded more than 60% conversion in the same time period. Moreover, even wild-type OYE 2.6 can reduce cyclohexenones with very bulky 4-substituents efficiently.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1890-25-1